Published in Gut on September 01, 2012
Cytokine patterns differ seasonally between women with and without uterine leiomyomata. Am J Reprod Immunol (2013) 1.99
Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol (2015) 0.94
Ulcerative colitis and perfluorooctanoic acid (PFOA) in a highly exposed population of community residents and workers in the mid-Ohio valley. Environ Health Perspect (2013) 0.88
What does irritable bowel syndrome share with non-alcoholic fatty liver disease? World J Gastroenterol (2013) 0.85
Th9 cells in inflammatory bowel diseases. Semin Immunopathol (2016) 0.84
Oleanolic acid controls allergic and inflammatory responses in experimental allergic conjunctivitis. PLoS One (2014) 0.80
Differential IL-13 production by small intestinal leukocytes in active coeliac disease versus refractory coeliac disease. Mediators Inflamm (2013) 0.79
Serum IL-17 and IL-6 increased accompany with TGF-β and IL-13 respectively in ulcerative colitis patients. Int J Clin Exp Med (2014) 0.78
Current stage in inflammatory bowel disease: What is next? World J Gastroenterol (2015) 0.78
Serum cytokine pattern in young children with screening detected coeliac disease. Clin Exp Immunol (2015) 0.78
Wrestlers' immune cells produce higher interleukin-6 and lower interleukin-12 and interleukin-13 in response to in vitro mitogen activation. Iran J Basic Med Sci (2014) 0.78
Interleukin-13 interferes with activation-induced t-cell apoptosis by repressing p53 expression. Cell Mol Immunol (2015) 0.77
Low serum interleukin-13 levels correlate with poorer prognoses for colorectal cancer patients. Int Surg (2014) 0.77
Semaphorin 3A controls allergic and inflammatory responses in experimental allergic conjunctivitis. Int J Ophthalmol (2015) 0.77
Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis. PLoS One (2016) 0.76
Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases. Gastroenterology (2016) 0.75
The immunological landscape in necrotising enterocolitis. Expert Rev Mol Med (2016) 0.75
Early Persistent Blood Eosinophilia in Necrotizing Enterocolitis Is a Predictor of Late Complications. Neonatology (2015) 0.75
Epidermal Growth Factor and Intestinal Barrier Function. Mediators Inflamm (2016) 0.75
Effect of predatory bacteria on the gut bacterial microbiota in rats. Sci Rep (2017) 0.75
Genetic deletion of the bacterial sensor NOD2 improves murine Crohn's disease-like ileitis independent of functional dysbiosis. Mucosal Immunol (2016) 0.75
IL-13/STAT6 signaling plays a critical role in the epithelial-mesenchymal transition of colorectal cancer cells. Oncotarget (2016) 0.75
Immune balance: the development of the idea and its applications. J Hist Biol (2014) 0.75
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35
Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis (2012) 3.69
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96
Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am J Gastroenterol (2013) 2.85
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol (2010) 2.74
The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 2.58
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis (2012) 2.55
Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut (2013) 2.03
Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology (2012) 2.03
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
Groups IV, V, and X phospholipases A2s in human neutrophils: role in eicosanoid production and gram-negative bacterial phospholipid hydrolysis. J Biol Chem (2001) 1.67
Anti-Saccharomyces cerevisiae antibodies: a stable marker for Crohn's disease during steroid and 5-aminosalicylic acid treatment. Am J Gastroenterol (2003) 1.54
Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis (2012) 1.49
Heterogeneous expression and regulation of CD40 in human hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2003) 1.40
The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol (2007) 1.39
Genetic variants of Wnt transcription factor TCF-4 (TCF7L2) putative promoter region are associated with small intestinal Crohn's disease. PLoS One (2009) 1.24
Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology (2010) 1.23
Optimising monitoring in the management of Crohn's disease: a physician's perspective. J Crohns Colitis (2013) 1.20
Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: phenotype-genotype correlations. World J Gastroenterol (2005) 1.19
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Diagnostic value of CT enteroclysis compared with conventional enteroclysis in patients with Crohn's disease. AJR Am J Roentgenol (2005) 1.11
Intestinal microbiota: a source of novel biomarkers in inflammatory bowel diseases? Best Pract Res Clin Gastroenterol (2013) 1.06
Specific systemic nonviral gene delivery to human hepatocellular carcinoma xenografts in SCID mice. Hepatology (2002) 1.04
Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC. Gastroenterology (2013) 1.03
Which patients with IBD need psychological interventions? A controlled study. Inflamm Bowel Dis (2008) 1.03
Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection. J Crohns Colitis (2009) 1.02
A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol (2005) 1.00
Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: results from CARE. Inflamm Bowel Dis (2011) 1.00
Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study. Inflamm Bowel Dis (2011) 1.00
Infliximab: lack of efficacy on perforating complications in Crohn's disease. Inflamm Bowel Dis (2004) 0.99
A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS One (2013) 0.97
Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol (2012) 0.97
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies. Adv Ther (2013) 0.96
6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol (2007) 0.94
Expression of the high-affinity IgG receptor FcRI (CD64) in patients with inflammatory bowel disease: a new biomarker for gastroenterologic diagnostics. Am J Gastroenterol (2009) 0.93
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis. Inflamm Bowel Dis (2010) 0.92
IBD patients need in health quality of care ECCO consensus. J Crohns Colitis (2008) 0.92
Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resection. Inflamm Bowel Dis (2010) 0.91
An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn's disease. Digestion (2003) 0.91
Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases. Eur J Clin Invest (2011) 0.90
Novel variants of the IL-10 receptor 1 affect inhibition of monocyte TNF-alpha production. J Immunol (2003) 0.90
The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am J Gastroenterol (2009) 0.90
Extracorporeal photopheresis: past, present, and future. J Am Acad Dermatol (2009) 0.89
Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur J Gastroenterol Hepatol (2003) 0.89
Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. Eur Radiol (2008) 0.88
Association of a functional variant in the Wnt co-receptor LRP6 with early onset ileal Crohn's disease. PLoS Genet (2012) 0.88
Briakinumab for treatment of Crohn's disease: results of a randomized trial. Inflamm Bowel Dis (2015) 0.86
Results of the 2nd scientific workshop of the ECCO (IV): therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. J Crohns Colitis (2012) 0.86
Ecobiotherapy Rich in Firmicutes Decreases Susceptibility to Colitis in a Humanized Gnotobiotic Mouse Model. Inflamm Bowel Dis (2015) 0.86
Factors impacting the results of interferon-γ release assay and tuberculin skin test in routine screening for latent tuberculosis in patients with inflammatory bowel diseases. Inflamm Bowel Dis (2010) 0.85
A systematic survey evaluating 6-thioguanine-related hepatotoxicity in patients with inflammatory bowel disease. Wien Klin Wochenschr (2007) 0.85
Tissue factor exposing microparticles in inflammatory bowel disease. J Crohns Colitis (2012) 0.84
Long-term follow-up of babies exposed to azathioprine in utero and via breastfeeding. J Crohns Colitis (2010) 0.84
Austrian infliximab experience in Crohn's disease: a nationwide cooperative study with long-term follow-up. Eur J Gastroenterol Hepatol (2004) 0.83
Three novel thiopurine S-methyltransferase allelic variants (TPMT*20, *21, *22) - association with decreased enzyme function. Hum Mutat (2006) 0.83
Thioguanin-induced nodular regenerative hyperplasia of the liver-ROC analysis of different MR techniques. Eur Radiol (2007) 0.83
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology (2012) 0.82
Drug monitoring of biologics in inflammatory bowel disease. Curr Opin Gastroenterol (2013) 0.82
Change in erythrocyte mean corpuscular volume during combination therapy with azathioprine and infliximab is associated with mucosal healing: a post hoc analysis from SONIC. Inflamm Bowel Dis (2015) 0.82
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trial. J Crohns Colitis (2012) 0.81
Safety and Efficacy of an Oral Inhibitor of the Purinergic Receptor P2X7 in Adult Patients with Moderately to Severely Active Crohn's Disease: A Randomized Placebo-controlled, Double-blind, Phase IIa Study. Inflamm Bowel Dis (2015) 0.81
Assessing the demand for psychological care in chronic diseases: development and validation of a questionnaire based on the example of inflammatory bowel disease. Inflamm Bowel Dis (2004) 0.79
Public awareness of Crohn's disease and ulcerative colitis: A national survey. J Crohns Colitis (2009) 0.79
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis (2009) 0.79
Renal insufficiency in IBD--prevalence and possible pathogenetic aspects. J Crohns Colitis (2013) 0.79
High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease. Am J Med (2012) 0.79
Simultaneous quantification of eleven thiopurine nucleotides by liquid chromatography-tandem mass spectrometry. Anal Chem (2012) 0.79
Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: results from an international survey and discussion programme. J Crohns Colitis (2011) 0.78
Systematic Review: Sequential Rescue Therapy in Severe Ulcerative Colitis: Do the Benefits Outweigh the Risks? Inflamm Bowel Dis (2015) 0.78
IL-10RA truncation mutations and Semite populations. Inflamm Bowel Dis (2010) 0.78
NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease. Am J Gastroenterol (2008) 0.78
Withdrawal of long-term maintenance treatment with azathioprine tends to increase relapse risk in patients with Crohn's disease. Dig Dis Sci (2014) 0.77
Efficacy of azathioprine versus mesalazine in postoperative Crohn's disease-the authors' response. Gut (2011) 0.76
Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. J Crohns Colitis (2010) 0.76
A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. Scand J Gastroenterol (2005) 0.76
Mucosal improvement in patients with moderate to severe postoperative endoscopic recurrence of Crohn's disease and azathioprine metabolite levels. Inflamm Bowel Dis (2013) 0.76
Are inherited thrombotic risk factors associated with fibrostenosis in Crohn's disease? Inflamm Bowel Dis (2011) 0.76
Impact of interobserver disagreement on phenotype-genotype associations in Crohn's disease. Inflamm Bowel Dis (2007) 0.76
Healthy offspring in parents both receiving thiopurines. Gastroenterology (2004) 0.75
Monocyte human leukocyte antigen-DR expression-a tool to distinguish intestinal bacterial infections from inflammatory bowel disease? Shock (2013) 0.75
Steroid dependency in Crohn's disease. Gastroenterology (2002) 0.75
The Importance and Challenges of Dietary Intervention Trials for Inflammatory Bowel Disease. Inflamm Bowel Dis (2017) 0.75
Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's disease. World J Gastroenterol (2006) 0.75
Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. Inflamm Bowel Dis (2017) 0.75
Complications in Crohn's disease: right-sided ureteric stenosis and hydronephrosis. Inflamm Bowel Dis (2007) 0.75
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. Expert Rev Clin Immunol (2014) 0.75
Systematic Review and Meta-analysis: Fecal Microbiota Transplantation for Treatment of Active Ulcerative Colitis. Inflamm Bowel Dis (2017) 0.75
[NOD2/CARD15 mutations and genotype-phenotype correlations in patients with Crohn's disease. Hungarian multicenter study]. Orv Hetil (2004) 0.75